Italia markets closed

Aclaris Therapeutics, Inc. (0H8T.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
14,70+1,61 (+12,34%)
Alla chiusura: 03:53PM BST
Schermo intero
Chiusura precedente13,08
Aperto14,70
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno14,70 - 14,70
Intervallo di 52 settimane14,70 - 14,70
Volume55
Media VolumeN/D
Capitalizzazione4,298M
Beta (5 anni mensile)0,60
Rapporto PE (ttm)N/D
EPS (ttm)-1,36
Prossima data utili31 ott 2022 - 04 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

    WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations. “We are very excited that we continue further strengthening our team through the addition of experienced industry veterans with successful track records,” said Neal Walker, Chief Executive Off

  • GlobeNewswire

    Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

    WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, which will be available on-demand beginning on Monday, September 12, 2022 at 7:00 a.m. ET. Management will be available September

  • GlobeNewswire

    Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata

    WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced a non-exclusive patent license agreement with Eli Lilly and Company (Lilly). Under the license agreement, Aclaris granted Lilly non-exclusive rights under certain patents and patent applications that Aclaris exclusively licenses from The Trustees of Columbia University in t